Kodiak Oil & Gas Corp. Downgraded by Wunderlich Securities; Endocyte Sinks on Recommendation to End Phase 3 Trial

Follow this company

Companies Mentioned

05/05/2014 [ACCESSWIRE]

Kodiak Oil & Gas Corp. (NYSE: KOG) - For an in-depth report on The Kodiak Oil & Gas Corp. follow: www.BullTrends.com/stockquote/KOG

Shares of KOG closed up 2.08% on Friday with about 18.3 million shares traded. The stock was one of the most active stocks on the NYSE after the company was downgraded by analysts at Wunderlich Securities. The firm lowered the stock from “buy” to “hold” and also lowered its price target to $14 from $17.

Endocyte, Inc. (NASDAQ: ECYT) - For an in-depth report on Endocyte, Inc. follow: www.BullTrends.com/stockquote/ECYT

Shares of Endocyte Inc. closed down 61.91% on about 17.7 million shares traded. The stock was one of the biggest decliners on the NASDAQ and hit a new yearly low of $6.50 during intra-day trading. The company announced that its phase 3 trial PROCEED was recommended to be stopped for futility following an interim analysis.

Terra Tech Corp. (OTC: TRTC) - For an in-depth report on Terra Tech Corp. follow: www.BullTrends.com/stockquote/TRTC

Shares of Terra Tech Corp. closed up 11.60% on Friday with nearly 2.5 million shares traded. The stock was one of the biggest gainers in the OTC market. Last month the company announced that its subsidiary Edible Garden’s line of living produce is now available at 75 new retails stores throughout the Northeast. The company is now distributing their line of sustainable and locally grown produce to Daves Marketplace in Rhode Island as well as Associated Grocers and Trucchi's Supermarkets in New England.

Expedia Inc. (NASDAQ: EXPE) - For an in-depth report on Expedia Inc. follow: www.BullTrends.com/stockquote/EXPE

Shares of EXPE closed down 3.68% on about 6.4 million shares traded on Friday. The stock was one of the most active on the NASDAQ. The company beat analysts' estimates for earnings in the first quarter. The company reported earnings of 16 cents a share, beating analysts' expectations of 15 cents a share by 1 cent. Revenue grew 18.85 year-over-year to $1.2 billion for the quarter. Analysts surveyed by Thomson Reuters expected $1.8 billion in revenue.


Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures. 


Leave a comment...

Your Name